Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:395-396 (16 August), doi:10.1136/bmj.327.7411.395-b
| The first 150 words of the full text of this article appear below. |
EDITORShulman et al report an increase in the prescription of valproate for elderly patients with bipolar disorder in Canada (and corresponding decrease in prescription of lithium).1 A similar pattern has been observed in the United States over the past decade or so.2 As the authors note, this change has occurred despite the limited evidence supporting the use of valproate and may indeed reflect concerns about lithium toxicity in elderly patients.
The BALANCE trial (www.psychiatry.ox.ac.uk/balance/), which is currently recruiting in the United Kingdom and soon to begin recruiting in the United States, should provide reliable evidence about the use of both lithium and valproate in bipolar disorder.3 A recent trial comparing lithium, valproate, and placebo did not find a significant difference between the treatments, probably because the inclusion of an untreated control arm meant that it was difficult to recruit patients who were judged at substantial risk
Jennifer M Rendell, BALANCE trial manager
jennifer.rendell@psych.ox.ac.uk
John R Geddes, professor of epidemiological psychiatry
Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX
Michael J Ostacher, instructor in psychiatry
Harvard Bipolar Research Program, Massachussetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA 02114, USA on behalf of the BALANCE Investigators
Read all Rapid Responses